P - Caution when used during pregnancy
L - Contraindicated in lactation
Cyproheptadine usually as cyproheptadine hydrochloride, trade name Periactin) is an antihistaminic/anticholinergic and antiserotonergic agent. It acts as a 5-HT2 receptor antagonist and also blocks calcium channels.
Cyproheptadine is a sedating antihistamine with antimuscarinic, serotonin-antagonist and calcium-channel blocking properties. It competes for H1-receptor sites on effector cells in the GIT, blood vessels and resp tract.
Absorption: Absorbed from the GIT (oral).
Metabolism: Completely hepatic.
Excretion: Via urine (as conjugates); via faeces.
Information Not Available
Slight to moderate drowsiness, fatigue; dry mouth, GI upsets, nausea; appetite increase, wt gain and impaired alertness.
General: Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with:
History of bronchial asthma
Increased intraocular pressure
Hyperthyroidism
Cardiovascular disease
Hypertension
Elderly; epilepsy; tasks requiring mental alertness; symptomatic prostate hypertrophy; epilepsy; alcoholism; pregnancy.
Masks ototoxicity produced by aminoglycosides and antibiotics.
Potentially Fatal: Potentiate CNS depressant actions of alcohol, barbiturates, sedatives, opioid analgesics and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and tricyclic antidepressants.
Information Not Available
Oral
Allergic conditions
Adult: As HCl: 4 mg tid adjusted as necessary. Usual dose range: 12-16 mg daily in 3-4 divided doses. Up to 32 mg daily may be used in some cases.
Child: As HCl: 2-6 yr: 2 mg tid (max: 12 mg daily); 7-14 yr: 4 mg bid-tid (max: 16 mg daily).
Elderly:
Oral
Treatment and prophylaxis of migraine and other vascular headaches
Adult: As HCl: 4 mg, may repeat 30 minutes later. Not to exceed 8 mg within a 4-6-hr period. Maintenance dose: 4 mg every 4-6 hr.
May be taken with or without food. (May be taken w/ meals to reduce GI discomfort.)
Caution when used during pregnancy.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters)
Contraindicated in lactation
Information Not Available
Information Not Available
Narrow-angle glaucoma; acute asthmatic attack; bladder neck obstruction; stenosing peptic ulcer; GIT obstruction; MAOIs therapy; hypersensitivity; neonates, lactation.
Oral: Store at 15-25°C
Oral: Store at 15-25°C
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.